Skip to content

Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease

Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease - Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000052579
Enrollment
50
Registered
2023-10-25
Start date
2023-10-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel syndrome

Interventions

None listed

Sponsors

Juntendo University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Of those who have decided to receive the zoster vaccine, all cases that meet the following conditions are eligible. 1. Patients with inflammatory bowel disease (remission to moderate) 2. Adult 3. Regardless of gender 4. Outpatient at the time of vaccination (regardless of hospitalization or outpatient at the time of consent) 5. Patients who have given their voluntary consent to participate in this study

Exclusion criteria

Exclusion criteria: The following patients are excluded from the standpoint of ensuring safety. 1. All cases with liver disease, renal disease, heart disease, or other serious complications that are judged inappropriate by the attending physician 2. Cases with other autoimmune diseases 3. All cases of lactating women, pregnant women or those who may be pregnant 4. Patients who are judged to be unsuitable by other doctors Among the above (1) research subjects, those who meet all (2) selection criteria and (3) none of the exclusion criteria are eligible.

Design outcomes

Primary

MeasureTime frame
Frequency of local and systemic adverse events

Secondary

MeasureTime frame
Effect of vaccination on primary disease of IBD

Countries

Japan

Contacts

Public ContactTomoyoshi Shibuya

Juntendo University Gastroenterology

tomoyosi@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026